The FDA granted a priority review to durvalumab (Imfinzi) in October for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation.
“Although the overall survival data in this study have yet to mature, the clinically meaningful difference in progression-free survival merits consideration of durvalumab as a new standard of care in this patient population,” they wrote.
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
- Rizvi NA, Peters S. Immunotherapy for unresectable stage III non–small-cell lung cancer. N Engl J Med. 2017; 377:1986-1988.
... to read the full story